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A B S T R A C T
Kv2.1, the voltage-gated ion channel, is ubiquitously expressed in variety of tissues and dysfunction of
this ion channel is responsible for multiple diseases. Electrophysiological properties of ion channels are
so far characterized with eukaryotic cells using the manual patch clamp which requires skilful operators
and expensive equipments. In this research, we created a simple and sensitive drug screen method using
bacterial giant spheroplasts and the automated patch clamp which does not require special skills. We
expressed a eukaryotic voltage-gated ion channel Kv2.1 in Escherichia coli using prokaryotic codon, and
prepared giant spheroplasts large enough for the patch clamp. Human Kv2.1 currents were successfully
recorded from giant spheroplasts with the automated system, and Kv2.1-expressed E. coli spheroplasts
could steadily reacted to the dose–response assay with TEA and 4-AP. Collectively, our results indicate for
the ﬁrst time that the bacterial giant spheroplast can be applied for practical pharmaceutical assay using
the automated patch clamp.
ã 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Ion channels play essential roles in wide range of biological
phenomena including neural transduction and muscle contraction
[9]. Voltage-gated K+ channels are ubiquitously expressed in
various organs including brain, heart, kidney, skeletal muscle,
retina and pancreas, and Kv2.1 is responsible for regulating
neurotransmitter release, heart rate, muscle contraction, insulin
secretion, and cell volume [21,25,17,11], which means many
diseases are related to the misconduct of this ion channel, making
Kv2.1 valuable pharmaceutical target.
Patch clamp, developed by [18], is the most sensitive technique
for ion channel analysis and has been the gold standard to
characterize electrophysiological properties of drug candidates
[3,10,24]. Patch clamp, so far, refers to the manual patch clamp
whose samples are typically tissue slices, Xenopus oocytes, yeasts,
cell lines and the lipid bilayer which are relatively easy to pick
manually under visual aids. Conventional manual patch clamp
requires skilful operators and expensive equipments and that is the
bottleneck of the high throughput screening of pharmaceutical
compounds [3]. In order to resolve this situation, several
automated patch clamp systems have been developed in the past
decade [24]. Automated patch clamp systems, such as Port-a-Patch
from Nanion has made electrophysiological observation accessible
for anyone thanks to the automated system and cost effectiveness
[10,24]. With this novel system, even if the operator was a patch
clamp beginner, high quality data can be obtained without fuss.
Escherichia coli, a Gram-negative bacterium, is the most
extensively characterized organism genetically and biochemically.
Many gene manipulation methods are already established to
handle E. coli and many mutants are available. Despite differences
in physiological background and the post-translational modiﬁca-
tion mechanism, multiple sequence alignment of eukaryotic and
prokaryotic voltage-gated channels indicates charged residues
within transmembrane helices are strikingly conserved [19], and
prokaryotic ion channels have almost the same physical properties
with eukaryotic channels and are comparable to eukaryotic
channels [16,20]. The bacterial membrane, therefore, can serve
as a valid model for studying channel structure [2]. Until now, E.
coli has been used only to produce foreign recombinant proteins,
yet the E. coli expression system can be also comparable to
eukaryotic expression systems like Xenopus oocytes for studying
heterologous ion channels. The use of E. coli has several technical
advantages over existing eukaryotic expression systems. In case of
expressing prokaryotic channels, their functions can be better
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reproduced in E. coli than using eukaryotic system. In addition,
since genetic code is mutual, the channel expression and its
electrophysiological characterization can be seamlessly accom-
plished by only one construct; we do not need to prepare mRNA in
eukaryotic code for Xenopus oocyte injection nor purify membrane
proteins for reconstitution in the lipid bilayer for patch clamp,
saving tremendous time and effort [13]. Furthermore, E. coli can be
used not only to express prokaryotic proteins but also to express
eukaryotic proteins. Although E. coli does not possess the
glycosylation machinery and the expression of eukaryotic mem-
brane proteins often turns out to be toxic to the bacterium, E. coli
can still be a feasible alternative to eukaryotic system. Precise
analysis of the target membrane protein is possible if knockout
strains were prepared to silence genes which interfere with the
exogenous target protein. Besides, if membrane proteins were
expressed in eukaryotic cells, they can be sorted into organelles,
not into the outermost plasma membrane; however, if E. coli was
selected for the expression system, membrane proteins are assured
to be expressed in the inner membrane, which is convenient for the
patch clamp [23]. Consequently, E. coli can be a realistic alternative
to eukaryotic systems for studying ion channels. The major
obstacle which makes the use of E. coli difﬁcult for patch clamp is
that bacterial cells are usually too small for patch clamp electrodes,
and not so many cases have been reported at this time. Ion
channels of E. coli have been studied with the patch clamp since its
development by Matrinac et al. [14], who made gigantic bacteria
called “snakes” using antiseptics and produced giant spheroplasts
large enough for the patch clamp by enzymatic digestion of the
elongated bacteria.
The combination of giant bacterial spheroplasts and the easy-
to-operate automated patch clamp system will prove extremely
powerful for primary drug candidate screening through charac-
terization of biophysical properties of membrane proteins.
The purpose of this project was to develop a simple and sensitive
pharmaceutical assay method using the bacterial giant spheroplast
and the automated patch clamp system. This paper describes the
process in which human Kv2.1 was expressed in E. coli cells which
are then digested to produce giant spheroplasts suitable for the
automated patch clamp; Kv2.1 currents were measured with the
automated patch clamps system and time-course recordings of
the dose–response assay were demonstrated by the administration
and wash-out of TEA (tetraethylammonium) and 4-AP
(4-aminopyridine).
2. Materials and methods
2.1. The E. coli strain and chemicals
Overnight Express C43 (DE3) SOLOs chemically competent cells
(Lucigen, Wisconsin, USA) were used for spheroplast preparation.
LB broth (Sigma, Missouri, USA) and Terriﬁc Broth (Fluka, Missouri,
USA) were prepared by manufacturers’ instruction. Ready-Lyse
Lysozyme (Epicenter, Chicago, USA) and OmniCleave Endonuclease
(Epicentre) were diluted to 1/5 with attached substrate diluents for
easier handling. D(+)-Glucose, sucrose, 1 M Tris–HCl, pH 8.0,
ampicillin, cephalexine, IPTG and TEA were purchased from Wako
(Osaka, Japan). Ampicillin, cephalexine and IPTG were prepared in
50 mg/ml, 10 mg/ml and 1 M, respectively. 4-AP and NFA (niﬂumic
acid) were purchased from Sigma (Missouri, USA).
2.2. Expression vector and transformation
The artiﬁcial gene of human Kv2.1 was synthesized using
prokaryotic codon (Operon Biotechnology, Tokyo, Japan) and
inserted into pET-23a vector (Novagen, Massachusetts, USA) at
BamHI site with In-Fusion HD Cloning Kit (Clontech, California,
USA) according to the manufacturer’s instruction. Then, Stellar
competent cells (Clontech) were transformed and seeded on
LB/Amp plate and the insert was conﬁrmed with colony check PCR.
The colony with right insert was cultured in 100 ml LB/Amp for
plasmid extraction by Plasmid Midi Kit (QIAGEN, Hilden, Germany)
using low-copy plasmid midiprep protocol. Overnight Express C43
(DE3) SOLOs chemically competent cells were then transformed
with the plasmid and plated on LB/Amp plates.
2.3. Western blotting
Single colony of Kv2.1-expressed C43 was inoculated with
100 ml Overnight Express Instant TB Medium (Novagen) and
incubated at 37 C for 4 h and 30 C for overnight with shaking of
200 rpm. C43 with plain pET vector was used as a control. The
culture was spun at 3000  g for 5 min to collect the pellet.
Membrane protein fractions were extracted from the C43 pellet
with ReadyPrep Protein Extraction Kit (Bio-Rad Laboratories,
California, USA) according to the manufacturer’s instruction.
Denatured samples were separated by SDS-PAGE using SuperSep
Ace 7.5% gel (Wako) at 200 V for 1 h. Proteins were transferred onto
0.2 mm PVDF membrane (Bio-Rad Laboratories) with Trans-Blot
Turbo Blotting System (Bio-Rad Laboratories), and 0.5% Block Ace
(DS Pharma Biomedical, Osaka, Japan) was used for blocking
overnight. The blotted membrane was exposed to primary
(His-probe (G-18) Rabbit polyclonal IgG, Santa Cruz Biotechnology,
Texas, USA) and secondary (Anti-Rabbit IgG heavy and light chain
HRP conjugated, Bethyl Laboratories, Texas, USA) antibody using
SNAP i.d. (Merck Millipore). The membrane was incubated with
ImmunoStar LD (Wako) at room temperature for 1 min and bands
were detected by C-DiGit Blot Scanner (LI-COR Biosciences,
Nebraska, USA).
2.4. Spheroplast preparation
E. coli spheroplasts were prepared by enzymatic digestion
described in these literatures [1,5,8,14]. In short, single colony of
E. coli was inoculated in 2 ml LB medium and cultured at 37 C with
the shaking of 220 rpm overnight. 200 ml of this pre-culture was
diluted into 20 ml TB medium with 20 ml of 50 mg/ml ampicillin
and cultured for 70 min. When the O.D.600 reached 0.12,
cephalexin, a septation inhibitor, was added to the ﬁnal
concentration of 60 mg/ml, and the elongation of bacterial
ﬁlaments, referred as “snakes” were continued for 2.5 h. At the
end of the culture, 1 mM IPTG was added and incubated at 37 C
with shaking for 20 min for Kv2.1 induction.
2 ml culture was then dispensed into 2 ml micro tubes and
“snakes” were harvested by centrifugation of 1000  g for 3 min.
The pellet was resuspended in 500 ml of 1 M glucose by gentle
tapping. The bacterial cell wall was digested by successively adding
30 ml 1 M Tris–HCl, pH 8.0, 2 ml (5760 U) diluted lysozyme, 2 ml
(80 U) diluted endonuclease, and 6 ml 125 mM EDTA, pH 8.0. The
tube was mixed every time the reagents were added by inverting
for several times, and incubated at room temperature for 10 min.
100 ml of stop solution (10 mM Tris–HCl, pH 8.0, 0.7 M sucrose,
20 mM MgCl2) was added to end digestion and spheroplast
suspension was stored at 80 C and used within 2 weeks from the
preparation.
On the day of electrophysiological recording, a tube of frozen
spheroplasts was thawed on ice and ﬁltered with 40 mm and
20 mm nylon mesh (Kyosin Riko, Tokyo, Japan) to remove large
debris. Filtered spheroplast suspension was then diluted to 10
times by adding 1 M glucose with 100 mM Tris–HCl, pH 8.0. Diluted
sample was loaded in a 15 ml syringe and sorted by particle size
using a spiral sorter chip (microﬂuidic ChipShop, Jena, Germany)
and a syringe pump (YMC Keyboard Chemistry, Kyoto, Japan) at a
18 K. Kikuchi et al. / Biotechnology Reports 7 (2015) 17–23
ﬂow rate of 0.5 ml/min. Spheroplasts sorted at outlet #4 of the
microﬂuidic chip were spun down at 700  g for 3 min and
resuspended in 50 ml 1 M glucose with 100 mM Tris–HCl, pH 8.0.
2.5. Electrophysiology
Whole-cell patch clamp recording of the E. coli spheroplast was
performed by the Port-a-Patch1 system (Nanion, München,
Germany) using NPC-1 borosilicate glass chips with a resistance
of 10–15 MV. All experiments were conducted at room tempera-
ture (22–27 C). The Nanion’s standard internal solution was
composed of 50 mM KCl, 10 mM NaCl, 60 mM KF, 20 mM EGTA,
10 mM Hepes, KOH, pH 7.2. For the external solution, 400 mM
sucrose was supplemented to the Nanion’s standard external
solution which contained 140 mM NaCl, 4 mM KCl, 1 mM MgCl2,
2 mM (experimental) or 5 mM (sealing) CaCl2, 5 mM glucose,
10 mM Hepes, NaOH, pH 7.4. 10 mM NFA was supplemented to
experimental solutions to block chloride current contamination.
For observation of Kv2.1 inhibition, 100 mM and 300 mM TEA and
1 mM and 10 mM 4-AP were added to the experimental solution.
First, the external solution with 5 mM Ca2+ was used for the
patch formation on the glass chip aperture. 5 ml of the spheroplast
suspension was applied to the well. Once the spheroplast achieved
the whole-cell recording conﬁguration, 5 mM Ca2+ solution was
replaced with 2 mM Ca2+ external solution using the external
perfusion module, leaving for at least 2 min until the membrane
became stable. The membrane usually got stable after 3–10 min
after membrane break-in in 2 mM Ca2+ external solution. Patches
were rejected if current levels were unstable during the recording,
and if currents following replacement with 2 mM Ca2+ external
solution did not recover to the baseline values, suggesting that
rundown of the patch had occurred.
K+ channel currents were recorded with the EPC-10 USB Patch
Clamp Ampliﬁer (HEKA Electronik Dr. Schulze GmbH, Germany),
and data acquisition and analysis were performed with Patch-
Master (HEKA Electronik). A voltage step protocol with 20 mV
increments was performed between 60 mV to +60 mV for 500 ms
duration with 15 s intervals from a holding potential of 80 mV to
observe Kv2.1 and endogenous K+ channel activity.
For observation of Kv2.1 current inhibition using TEA and 4-AP,
control currents were ﬁrst measured in 2 mM Ca2+ external
solution for 4 min at 12 points when the membrane became stable.
Then 2 mM Ca2+ external solution supplemented with TEA or 4-AP
was applied into the well using the external perfusion system and
the currents were measured for 4 min at 12 points. After one set of
the recording was ﬁnished, the inhibitor was immediately washed
out with 2 mM Ca2+ external solution. A time-course pharmacology
protocol was used to monitor Kv2.1 currents by giving +40 mV
pulses for 500 ms duration from a holding potential of 80 mV
with 20 ms intervals. Current recording was initiated 3–10 min
after the membrane break-in, and continued up to 60 min as long
as the membrane was stable.
2.6. Data analysis
To analyze Kv2.1 current modulation with TEA and 4-AP, ﬁrst
and last points of each measuring section were omitted and mid 10
points were used for calculation. Currents were ﬁrst normalized to
the average of 10 wash-out current magnitudes prior to inhibitor
administration. Extreme values were excluded with
Smirnov–Grubbs test. Statistical signiﬁcance was determined by
Tukey–Kramer test. P values of <0.05 were considered signiﬁcant,
and results are indicated as means  S.E.M.
Fig. 1. E. coli giant spheroplast preparation.
(a) C43 in the original culture. (b) C43 cultured for 3 h in presence of 60 mg/ml
cephalexin. Bacteria were elongated to become “snakes” ranging 100–150 mm. (c)
Bacterial “snakes” were digested with 5760 U lysozyme and 80 U DNase to produce
giant spheroplasts ranging 1–7 mm in diameter. (d) A giant spheroplast suitable for
the patch clamp recording looks dark-colored (upper right); a shady and fragile
“ghost” spheroplast was located on lower left of the dark-colored spheroplast.
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3. Results
3.1. Spheroplast morphology
During the culture with 60 mg/ml cephalexin, bacterial “snakes”
elongated to 100–150 mm (Fig. 1a–b) and their digestion with
enzymes produced spheroplasts ranging F 1–7 mm (Fig. 1c).
Enzymatic digestion of bacterial snakes produced 4 types of
spheroplasts: large (F 4–7 mm) and gray, medium (F 2–4 mm) and
gray, small (less than 2 mm) and shiny, and shady and transparent
ones referred as “ghosts”.
3.2. Spheroplast sorting by particle size
Large spheroplasts between F 4 and 7 mm were successfully
separated by microﬂuidic chips (Fig. 4a) and the selected
spheroplasts were condensed at 700  g centrifugation (Fig. 4c).
Majority of smaller spheroplasts and debris were sorted into other
outlets of the chip (Fig. 4d); however, some population of small
spheroplasts could not be completely excluded from the popula-
tion of large spheroplasts. Besides, microﬂuidic chips did not
discriminate the condition of the spheroplast membrane; there-
fore, ghost spheroplasts were also sorted into the selected fraction
as long as the particle size was between F 4 and 7 mm. Although
some small spheroplasts and fragile ghost spheroplasts could not
be perfectly removed from the selected fraction, 90% of acquired
patches reached giga-seal within 2 min from the sample applica-
tion into the well, and 70% of the acquired patches were in
sufﬁcient conditions for electrophysiological recording.
3.3. Kv2.1 current recording
Human Kv2.1 was expressed in C43 and the expression was
conﬁrmed with the western blotting (Fig. 2a). Human Kv2.1
currents were successfully monitored with the Port-a-Patch
automated patch clamp system and the representative traces of
Kv2.1 and endogenous K+ channels evoked by the voltage-step
protocol between 60 mV and +60 mV were shown in Fig. 2b. As
summarized in Fig. 2c, the average current from C43 spheroplasts
expressing human Kv2.1 was signiﬁcantly higher than C43
spheroplasts transformed with control vector at voltage steps
over 40 mV (P < 0.05). 10 mM NFA was added to one group of
native K+ and Kv2.1 measurements to avoid chloride current
contamination; still native K+ current magnitudes were not altered
signiﬁcantly at all voltage steps by the presence of NFA in the
system (P < 0.05).
3.4. Kv2.1 current inhibition with TEA and 4-AP
Human Kv2.1-expressed C43 giant spheroplasts steadily
responded to the repeated administration of inhibitors and wash
solution. Once a strong seal was achieved, the spheroplast was
stable for 30 min for most of times, and even lasted for 60 min.
Fig. 3a shows a representative time-course recording of Kv2.1
current inhibition with TEA administration and the current
recovery with wash-out. The Kv2.1 current blocked by TEA always
returned to the original control level as soon as the well was
ﬂushed with 2 mM Ca2+ external solution. In addition, Kv2.1-
expressed giant spheroplasts reacted to TEA with dose-dependent
manner. As shown in Fig. 3b,100 mM and 300 mM TEA signiﬁcantly
Fig. 2. Human Kv2.1 expressed in C43.
(a) Kv2.1 bands, estimated to be 97 kDa, were detected in Kv2.1-expressed C43 (lane
3) and BL21 (lane 4) by western blotting; no bands were detected from C43 (lane 1)
and BL21 (lane 2) with control vector. BL21 was used for expression check only. (b)
Representative traces showing outward K+ currents triggered by a series of pulses
(from 60 mV to +60 mV, 500 ms) from a holding potential of 80 mV in plain C43
spheroplasts (upper) and spheroplasts expressing human Kv2.1 channel (lower). (c) IV-
relationship summary of (b). Results are indicated as mean  S.E.M. of 18 measurement
for native K+ channel with no NFA, 17 for native K+ channel with 10 mM NFA and 12 for
Kv2.1 with 10 mM NFA, respectively. *, signiﬁcantly higher (P < 0.05) than native K+
channels.
20 K. Kikuchi et al. / Biotechnology Reports 7 (2015) 17–23
reduced Kv2.1 current magnitudes (0.706  0.009 and
0.569  0.009, respectively; P < 0.05) to the control. Furthermore,
Kv2.1 current inhibition was observed using another K+ channel
inhibitor, 4-AP. Kv2.1 currents returned to the control level with
wash-out and were suppressed dose-dependent manner, like
observed in TEA. Fig. 3c shows that 1 mM and 10 mM 4-AP
signiﬁcantly reduced Kv2.1 current magnitudes (0.667  0.023 and
0.481 0.019, respectively; P < 0.05) to the control.
4. Discussion
4.1. The density and the uniformity of the sample count for the
automated patch clamp
In order to use bacterial spheroplasts for automated patch
clamp system, the spheroplast suspension needed to be dense and
uniform. In our preliminary experiment with spheroplast sample
without size selection, only 20% of all acquired patches reached
giga-seal, whose success coincided with the percentage of large
and gray spheroplasts present in whole spheroplast suspension.
According to the past reports, ideal whole-cell patches could be
obtained with large and gray spheroplasts, and no stable results
were obtained with “ghost” spheroplasts which were leaky and
fragile, and with small and shiny spheroplasts which were simply
hard to catch with the electrode [1,8]. So, we isolated large
spheroplast population ranging F 4–7 mm with microﬂuidic chips
which were capable of sorting particles by inertial force and
condensed the selected fraction with centrifugation. In result, the
automated system can now capture spheroplasts within 10 s from
the sample application to the well and 90% reached giga-seal in
2 min; 70% of all obtained patches were good enough for
electrophysiological recording. When spheroplast sample was
condensed by simple centrifugation without size selection,
Port-a-Patch caught spheroplasts within 10 s from the sample
application but only 20% of the acquired patches were good for
recording; when untreated spheroplast suspension was used for
Port-a-Patch, the apparatus needed 2 min, or often failed, to
capture a spheroplast. The automated patch captured spheroplasts
efﬁciently when concentration of the spheroplast suspension was
over 1 107 spheroplasts/ml, which was in the range reported by
[4] for cells (5 105–5 107 cells/ml). The microﬂuidic sorter chip
not only accelerated the experimental processes but also saved
time; if ultracentrifugation had been used for separating spher-
oplasts of desired size, it would have taken more than 2 h, while
pumping the sample through a sorter chip took only 11 min and
700G spin-down with an ordinary microcentrifuge took 3 min.
4.2. The patch clamp detects subtle membrane protein expression
The automated patch clamp system stably obtained sensible
Kv2.1 current readings from the bacterial giant spheroplast.
Sparsely-expressed ion channels in the membrane are hard to
detect with immunological assays. As shown in the result, Kv2.1
expression was barely observed with western blotting after the
tedious membrane protein extraction by ultracentrifugation and
the detection with the latest scanner, while the patch clamp could
sharply detect such a subtle but important signal in the bacterial
membrane. The patch clamp clearly reveals the presence of
weakly-expressed membrane proteins which could be otherwise
overlooked so far, giving detailed biophysical properties.
4.3. Stable drug assays were achieved by bacterial spheroplasts
Time-course observation of Kv2.1 channel was ﬁnely achieved
with the E. coli spheroplast using the external perfusion unit. Kv2.1
currents sharply responded to TEA and 4-AP administration and
rapid wash and the dose–response relationship could be observed
stably for 30 min in average.
Fig. 3. Kv2.1 inhibition with TEA and 4-AP.
(a) Representative time-course recording of Kv2.1 currents. This spheroplast had been stable for almost 1 h, enduring repeated drug administration and wash with 100 mM or
300 mM TEA and 2 mM Ca2+ solution. (b) The inhibition of Kv2.1 currents with TEA was observed by giving +40 mV pulses (500 ms) with 20 s intervals from a holding potential
of 80 mV. Current recording was initiated 10 min after the membrane break-in, and lasted 30–60 min while the membrane kept stability. Current magnitudes were
normalized to the wash current magnitude immediately before the TEA addition. Results are mean  S.E.M. for 60 sweeps from 6 separate experiments. *, signiﬁcantly lower
(P < 0.05) than 2 mM Ca2+ control; **, signiﬁcantly lower (P < 0.05) than 2 mM Ca2+ control and 100 mM TEA. (c) The inhibition of Kv2.1 currents with 4-AP was observed in the
same way with TEA. Results are mean  S.E.M. for 10 sweeps from 2 separate experiments. 10 mM NFA was added to avoid chloride channel current. *, signiﬁcantly lower
(P < 0.05) than 2 mM Ca2+ control; **, signiﬁcantly lower (P < 0.05) than 2 mM Ca2+ control and 1 mM 4-AP.
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4.4. More advantages of bacterial spheroplasts
As stated in the introduction, the bacterial giant spheroplast has
many technical beneﬁts over eukaryotic system and liposome
reconstitution. In addition to these advantages, the bacterial
spheroplast can be a better option when the target protein is
ligand-gated ion channel because rapid exchange of bath solution
is necessary for dose–response assays, and rapid wash-out is
difﬁcult to accomplish with the planner lipid bilayer patch.
Moreover, the orientation of the membrane protein polarity is
correctly arranged in the natural bacterial membrane while the
orientation of the protein insertion cannot be controlled in the
artiﬁcial lipid bilayer [13]. Again, the most important advantage of
all is that the direct use of bacterial spheroplasts can skip
painstaking steps needed to set up the eukaryotic system for
electrophysiological analysis. Now we are reﬁning a novel
technique named PERRIS (intra periplasm secretion and selection)
method, a kind of in vitro directed evolution in which a target
protein and the interacting peptide are expressed in E. coli inner
membrane and periplasmic space, respectively, to search and
optimize interacting peptides [12]. In this process, tremendous
number of recombinant E. coli would be produced and we needed a
fast and inexpensive way of primary screening. It is true that fancy
multi-channel automated patch clamp gears are available today
and using eukaryotic cells is much better for screening; however,
many laboratories in the world are still using E. coli for genetic
research and many of them would not be able to afford such
expensive equipments. Relatively affordable single channel patch
clamp and the direct use of bacterial spheroplasts may help
researchers in small labs not to give up electrophysiological studies
simply because of the budget problem.
4.5. Many ion channels are awaiting to be screened as pharmaceutical
targets.
Today membrane proteins occupy the large number of
promising pharmaceutical targets; of 6650 predicted potential
drug targets, G-protein-coupled receptors and ion channels
comprise of 30% and 15%, respectively [22]. Ion channel
modulators are attracting interests these years due to their
pharmacological values which can treat various diseases such as
hypertension, long QT syndrome, diabetes, epilepsy, schizophre-
nia, depression and pain [6,7,15]. Our novel method, the
combination of the bacterial spheroplast and the automated patch
clamp system, will be able to evaluate the interaction of these
membrane proteins and drug candidates with great details
without annoying manipulation. Furthermore, with the introduc-
tion of the multi-channel automated patch clamp and the
spheroplast fractionation, this screening method will become
even more powerful and expedite the screening process in future.
5. Conclusion
The eukaryotic voltage-gated ion channel Kv2.1 was expressed
in E. coli cells and giant spheroplasts large enough for the patch
clamp were prepared. Human Kv2.1 currents could be successfully
recorded from the giant spheroplast with the automated planner
patch clamp which did not require any special skills for handling.
Kv2.1-expressed E. coli spheroplasts could be stably used for the
dose-response assay with time-course recording using TEA and
4-AP, making it the ﬁrst application of the bacterial giant
spheroplast for practical pharmaceutical assay using the automat-
ed patch clamp system.
Fig. 4. Spheroplast separation by particle size.
Spheroplast suspension was sorted by particle size using spiral sorter chips. (a)
Outlet ports of a spiral sorter chip. (b) Untreated spheroplast sample. Many
undigested “snakes” and debris were present and large spheroplasts were sparsely
distributed. (c) Large spheroplasts between F 4 and 7 mm were sorted to the outlet
#4. (d) Middle-sized spheroplasts between F 2 and 4 mm were sorted to the outlet
#3. Even smaller spheroplasts and debris were sorted to the outlet #1 and #2.
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